HanchorBio Presents at WIC-APAC 2026: The CD47 Field Enters a New Design Era
Presentation highlights engineered CD47–SIRPα blockade and combination-ready checkpoint design
[Taipei, Shanghai, San Francisco | March 30, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for immuno-oncology and immune-related diseases, today announced that Alvin Luk, PhD, MBA, CCRA, President & Chief Medical Officer (Group) and CEO (USA) of HanchorBio, presented at WIC-APAC 2026 in Taipei on March 29, 2026.
In the presentation, “Reprogramming the CD47-SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering,” Dr. Luk argued that the CD47 field is now being redefined less by target validation than by therapeutic design. The presentation highlighted a key translational lesson from first-generation CD47 programs: biologic relevance was established, but on-target hematologic toxicity constrained the therapeutic window and limited clinical utility.
Dr. Luk further discussed how engineered SIRPα-Fc approaches may help address that challenge by preserving macrophage-mediated antitumor activity while improving hematologic tolerability, sustaining target engagement, and enabling more clinically usable combination strategies. He also placed this design logic in a broader strategic context, positioning it as a foundation for next-generation multi-checkpoint therapeutics spanning innate and adaptive immunity.
“First-generation CD47 programs helped establish the biologic relevance of the pathway, but they also made clear that hematologic liability was the critical translational barrier,” said Dr. Luk. “The opportunity now is not simply to revisit the mechanism, but to redesign it – preserving meaningful innate immune activity while building molecules with a wider therapeutic window and greater combination potential.”
During the session, Dr. Luk emphasized HanchorBio’s clinical and translational perspective on HCB101, an AI-guided, structurally engineered SIRPα-IgG4 Fc fusion protein designed to selectively block the CD47-SIRPα axis while minimizing hematologic toxicity that limited earlier CD47-directed methods. He also discussed how this work might contribute to the development of broader multi-functional checkpoint programs based on HanchorBio’s Fc-Based Designer Biologics (FBDB™) platform.
WIC-APAC 2026 also marked Dr. Luk’s first presentation of HanchorBio in Taiwan in his current leadership capacity.
Presentation Details
Conference: World Immunotherapy Council Asia-Pacific Conference (WIC-APAC 2026)
Date: March 29, 2026
Location: Taipei, Taiwan
Presentation Title: Reprogramming the CD47-SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering
This session was moderated by Dr. Peter Mu-Hsin Chang, an attending physician in the Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, and Associate Professor at the Institute of Biopharmaceutical Sciences, National Yang Ming Chiao Tung University. Dr. Chang specializes in head and neck cancer, medical oncology, and immunotherapy-related research, with extensive experience in clinical trials and translational medicine.
Speaker Profile
Dr. Luk is a global biotechnology executive with more than 30 years of leadership experience across translational medicine, clinical development, regulatory strategy, medical affairs, and strategic partnering. His career has focused on advancing innovative therapeutics from early development through global clinical execution, regulatory milestones, and commercialization across the U.S., EU, and Asia. At HanchorBio, he leads global corporate and development strategy and oversees clinical development, regulatory strategy, and medical affairs for the company’s HCB portfolio, including HCB101 and HCB301.
About WIC-APAC
The World Immunotherapy Council (WIC) is an international organization focused on advancing immunotherapy through scientific exchange and global collaboration. WIC-APAC brings together clinical experts, researchers, and healthcare professionals from across the Asia-Pacific region to discuss advances in cancer immunology and immunotherapy.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities intended to engage both innate and adaptive immune pathways. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through rational molecular engineering and scalable CMC strategies.
漢康生技於世界免疫治療聯盟亞太區大會發表：CD47 領域邁入全新設計時代
聚焦工程化 CD47–SIRPα 阻斷策略與可組合應用的免疫檢查點設計
漢康生技，一家致力於推動次世代免疫療法、聚焦腫瘤免疫與免疫相關疾病的全球臨床階段生技公司，昨日（29日）其集團總裁暨醫療長兼美國漢康執行長陸英明在台北舉行的世界免疫治療聯盟亞太區大會 (WIC-APAC 2026) 發表專題演講。
在題為「Reprogramming the CD47-SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering」的演講中，陸英明博士指出，CD47 領域的發展正逐漸從「靶點驗證」轉向「治療設計」的重新定義。本次演講強調第一代 CD47 計畫所帶來的重要轉譯經驗：雖然已證實其生物學相關性，但因為標靶相關的血液學毒性限制了治療視窗，進而影響其臨床應用價值。
陸英明博士進一步說明，工程化的 SIRPα-Fc 策略有望解決上述挑戰，透過在保留巨噬細胞介導抗腫瘤活性的同時，提升血液學耐受性、維持標的結合能力，並使更多具臨床可行性的聯合療法得以實現。他亦將此設計邏輯置於更宏觀的策略框架中，視其為橫跨先天與適應免疫的次世代多重檢查點療法的重要基礎。
「第一代 CD47 計畫確立了此路徑的生物學重要性，但同時也清楚顯示血液學毒性是關鍵的轉譯障礙，」陸英明博士表示。「現在的機會不只是重新檢視機制，而是重新設計它——在保留有意義的先天免疫活性的同時，打造具有更寬治療窗與更高聯合治療潛力的分子。」
在會中，陸英明博士亦強調漢康生技對 HCB101 的臨床與轉譯觀點。HCB101 為一項透過 AI 輔助設計、結構工程優化的 SIRPα-IgG4 Fc 融合蛋白，旨在選擇性阻斷 CD47-SIRPα路徑，同時降低早期 CD47 治療策略所面臨的血液學毒性。他亦說明此項研究如何進一步推動基於漢康 Fc-Based Designer Biologics（FBDB™）平台的多功能免疫檢查點療法開發。
此次世界免疫治療聯盟亞太區大會亦為陸英明博士在現任職務下首次於台灣代表漢康生技進行公開發表。
演講資訊
會議名稱：世界免疫治療聯盟亞太區大會World Immunotherapy Council Asia-Pacific Conference（WIC-APAC 2026）
日期：2026年3月29日
地點：台灣台北
講題：
Reprogramming the CD47-SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering
本場論壇由台北榮民總醫院腫瘤醫學部腫瘤內科主治醫師張牧新醫師（Dr. Peter Mu-Hsin Chang） 擔任主持人，同時亦為國立陽明交通大學生物藥學研究所副教授。張醫師長期深耕頭頸癌與腫瘤內科治療，並持續參與臨床試驗及新藥開發，兼具第一線臨床實務與轉譯研究經驗。其專業聚焦於頭頸癌、惡性腫瘤治療及免疫治療相關研究，並累積多篇臨床研究成果。
講者介紹
陸英明博士為全球生技產業資深領導者，擁有超過30年經驗，涵蓋轉譯醫學、臨床開發、法規策略、醫學事務及策略合作等領域。其職涯專注於推動創新療法自早期研發走向全球臨床執行、法規里程碑及商業化，橫跨美國、歐洲與亞洲。
於漢康生技，陸博士負責全球公司與研發策略，並領導臨床開發、法規策略與醫學事務，涵蓋公司 HCB 產品組合（包括 HCB101 與 HCB301）。
關於世界免疫治療聯盟亞太區大會 WIC-APAC
World Immunotherapy Council（WIC）為一國際組織，致力於透過科學交流與全球合作推動免疫治療發展。WIC-APAC 匯集來自亞太地區的臨床專家、研究人員與醫療專業人士，共同探討癌症免疫學與免疫治療的最新進展。
關於漢康生技
漢康生技總部位於台北、上海與舊金山灣區，是一家專注於腫瘤免疫與免疫相關疾病的全球臨床階段生技公司。其專有 Fc-Based Designer Biologics（FBDB™）平台可設計具多重功能的生物藥，透過多元標的組合，同時活化先天與適應免疫機制。
公司正推進一系列具差異化的創新生物藥產品組合，透過理性分子工程設計與可擴展的製程開發（CMC）策略，致力於解決重大未被滿足的醫療需求。